Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort

• Tipo: Artigo em Revista Científica Internacional
• Data: 2022

Autores

Pintalhão M (Autor) FMUP; Vasques Novoa, F (Autor) FMUP; Couto Viana, B (Autor) Outra; Pimentel, MJ (Autor) Outra; Neves, JS (Autor) FMUP; Mendonça, Luís (Autor) FMUP; Saraiva, F (Autor) Outra; Andre P Lourenco (Autor) FMUP; Ferreira, G (Autor) Outra; Filipe Macedo (Autor) FMUP; Araújo JP (Autor) FMUP; von Hafe P (Autor) FMUP; Almeida, J (Autor) Outra; Ferreira, JP (Autor) FMUP; Castro-Chaves P (Autor) FMUP; Leite-Moreira AF (Autor) FMUP

Revista

Título: International Journal of Cardiology

Vol. 365

Páginas: 87-90

ISSN: 0167-5273

Editora: Elsevier

Indexação

ISI Web of Knowledge - 1 Citação

Scopus - 2 Citações

Outras Informações

ID Authenticus: P-00X-13Q

DOI: 10.1016/j.ijcard.2022.07.037

Abstract (EN): Aims: The role of relaxin-2 as a circulating marker in heart failure (HF) with preserved ejection fraction (HFpEF) is poorly understood. We aimed to characterize relaxin-2 circulating levels in a population of chronic HFpEF patients and their association with long-term prognosis. Methods: Relaxin-2 serum levels were measured in 85 chronic HFpEF patients from a prospective cohort study (NETDiamond). Clinical, imaging, and analytical data were compared across relaxin-2 tertiles. The primary outcome was a composite of cardiovascular death, HF hospitalisation, acute HF episode or diuretic intensification and the secondary outcome a composite of cardiovascular death and total HF hospitalisations. Cox regression and negative binomial models were used to assess the relation between relaxin-2 and the outcomes. Results: Relaxin-2 levels were positively associated with left atrial volume, left ventricular mass and peripheral oedema, and negatively associated with ischemic heart disease and statin use. Higher relaxin-2 levels were associated with an increased risk of primary outcome, even after adjustment for age, B-type natriuretic peptide (BNP) and glomerular filtration rate (eGFR) (adjusted HR = 2.80, 95%CI 1.4-7.3, p = 0.034 for tertile 3). They were also associated with the occurrence of the secondary outcome (Incidence Rate Ratio = 5.28, 95%CI 1.2-23.2, p = 0.027), but this significance was lost when simultaneously adjusted for BNP and eGFR. Conclusion: In chronic HFpEF patients, higher relaxin-2 circulating levels were associated with left chambers remodelling, congestion, and adverse prognosis. These findings support a potential role for relaxin-2 as a pathophysiological agent and as a circulating biomarker in HFpEF.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 4